ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

All Content

The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.

Patients diagnosed with colorectal cancer at younger ages are more likely to have an underlying hereditary syndrome than older patients, according to a new study.

In a phase I study, gemcitabine given concurrently with fixed-dose EBRT showed promising results following surgery in patients with high-risk soft-tissue sarcoma.

A pair of studies suggest that aromatase inhibitors and bisphosphonates can each improve survival for postmenopausal women with early breast cancer.

Two trials reported marginal or no improvement in survival with nodal irradiation in early breast cancer patients, though reductions were seen in recurrence.

Adding tivantinib to erlotinib improved progression-free survival but not overall survival in patients with previously treated non-small-cell lung cancer.

The use of BEAMing technology on circulating DNA to identify multiple mutations in real time could help guide treatment in colorectal cancer patients.

The FDA has granted Orphan Drug Designation to the immunotherapy DPX-Survivac, which is in development for the treatment of ovarian cancer.

The consumption of alcohol has been linked with many different types of cancers. In this slide show we take a look at studies that looked into whether alcohol was associated with a greater risk of breast cancer, prostate cancer, colorectal cancer, and more.

Researchers have identified a subset of six biomarkers that together may predict the risk of more aggressive prostate cancer among African American men.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.